Skip to content

Investigating the Impact of Blood Purification (DFPP) on Lifestyle-related Diseases

Investigation of the Effects of Blood Purification (Double Filtration Plasmapheresis) on Lifestyle-related Disease Parameters

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1032240680
Enrollment
Unknown
Registered
2025-02-17
Start date
2025-02-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lifestyle-related Diseases, Arteriosclerosis Lifestyle-related Diseases, Arteriosclerosis

Interventions

None listed

Sponsors

TSUKADA NORIMASA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The study will include patients (subjects) who meet all of the following inclusion criteria and do not fall under any of the exclusion criteria. Inclusion Criteria: Healthy individuals (male or female) aged 20 years or older Individuals undergoing blood purification therapy at this hospital Individuals with a FIB-4 index of 1.3 or higher and a BMI of 27 or higher Individuals who have provided written informed consent to participate in this study Individuals who can undergo regular clinical examinations at this hospital (at weeks 8, 16, and 24)

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Patients with dyslipidemia or diabetes Individuals currently taking medications that affect metabolic function Pregnant women, patients who may be pregnant, or breastfeeding women Individuals with psychiatric complications or other conditions that may interfere with the ability to provide informed consent or comply with urine collection procedures Patients with severe cardiovascular, pulmonary, hepatic, or renal diseases who are currently undergoing treatment or are at risk of developing such conditions Any other individuals deemed unsuitable for the study based on the physician's judgment

Design outcomes

Primary

MeasureTime frame
The primary endpoints will be the analysis of clinical laboratory values and the assessment of safety.

Contacts

Public ContactHideo Kobayashi

Japan Society of Clinical Study for Frontier-Medicine

cro@jscsf.net+81-355421597

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026